Considering the Changing Treatment Landscape for Patients With Melanoma
Source: Targeted Oncology, December 2024
Evan Lipson, MD, an associate professor of oncology at John Hopkins School of Medicine and a head and neck oncologist at John Hopkins Medicine, discusses the evolving treatment landscape for advanced melanoma.
During a Case-Based Roundtable meeting, Lipson and participants talked about the complexity of choosing the right therapy for each patient at the appropriate time due to the abundance of new treatment options. He emphasizes the need for oncologists to share experiences and collaborate on the best sequence of these therapies.
Key considerations include efficacy, longevity of response, and toxicity profiles of the drugs, both individually and in combination. The discussion highlights the importance of understanding drug interactions and their outcomes in terms of adverse events and tumor response durability.